首页 > 最新文献

Allergy最新文献

英文 中文
Bioactive Mediator Profile of Mepolizumab‐Treated Eosinophilic Granulomatosis With Polyangiitis 美泊利珠单抗治疗嗜酸性粒细胞增多性多血管炎的生物活性介质谱
IF 12.4 1区 医学 Q1 ALLERGY Pub Date : 2024-11-11 DOI: 10.1111/all.16395
Yosuke Kamide, Kyuto Sonehara, Kiyoshi Sekiya, Shigeharu Ueki, Yuto Nakamura, Yukinori Okada, Masami Taniguchi
{"title":"Bioactive Mediator Profile of Mepolizumab‐Treated Eosinophilic Granulomatosis With Polyangiitis","authors":"Yosuke Kamide, Kyuto Sonehara, Kiyoshi Sekiya, Shigeharu Ueki, Yuto Nakamura, Yukinori Okada, Masami Taniguchi","doi":"10.1111/all.16395","DOIUrl":"https://doi.org/10.1111/all.16395","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"70 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142598098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Gestational Supplementation With 2′‐Fucosyllactose Is an Effective Strategy to Prevent Food Allergy 妊娠期补充 2′-岩藻糖是预防食物过敏的有效策略
IF 12.4 1区 医学 Q1 ALLERGY Pub Date : 2024-11-11 DOI: 10.1111/all.16396
A. Rousseaux, B. Misme‐Aucouturier, M. Le Romancer, R. Villette, M. Larsen, M. De Carvalho, G. Bouchaud, E. Perrin, S. Barbarot, C. Brosseau, M. Bodinier
{"title":"A Gestational Supplementation With 2′‐Fucosyllactose Is an Effective Strategy to Prevent Food Allergy","authors":"A. Rousseaux, B. Misme‐Aucouturier, M. Le Romancer, R. Villette, M. Larsen, M. De Carvalho, G. Bouchaud, E. Perrin, S. Barbarot, C. Brosseau, M. Bodinier","doi":"10.1111/all.16396","DOIUrl":"https://doi.org/10.1111/all.16396","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"36 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142598101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biologics and airway remodeling in asthma: early, late, and potential preventive effects 生物制剂与哮喘的气道重塑:早期、晚期和潜在的预防效果
IF 12.4 1区 医学 Q1 ALLERGY Pub Date : 2024-11-09 DOI: 10.1111/all.16382
G. Varricchi, R. Poto, M. Lommatzsch, G. Brusselle, F. Braido, J. C. Virchow, G. W. Canonica
Although airway remodeling in severe and/or fatal asthma is stil considered irreversible, its individual components as a cause of clinical symptoms and/or lung function changes remain largely unknown. While inhaled glucocorticoids have not consistently been shown to affect airway remodeling, biologics targeting specific pathways of airway inflammation have been shown to improve lung function, mucus plugging, and airway structural changes that can exceed those seen with glucocorticoids. This superiority of biologic treatment, which cannot be solely explained by insufficient doses or limited durations of glucocorticoid therapies, needs to be further explored. For this field of research, we propose a novel classification of the potential effects of biologics on airway remodeling into three temporal effects: early effects (days to weeks, primarily modulating inflammatory processes), late effects (months to years, predominantly affecting structural changes), and potential preventive effects (outcomes of early treatment with biologics). For the identification of potential preventive effects of biologics, we call for studies exploring the impact of early biological treatment on airway remodeling in patients with moderate‐to‐severe asthma, which should be accompanied by a long‐term evaluation of clinical parameters, biomarkers, treatment burden, and socioeconomic implications.
虽然严重和/或致命性哮喘的气道重塑一直被认为是不可逆的,但其作为临床症状和/或肺功能变化原因的各个组成部分在很大程度上仍不为人所知。虽然吸入性糖皮质激素尚未被一致证明能影响气道重塑,但针对气道炎症特定途径的生物制剂已被证明能改善肺功能、粘液堵塞和气道结构变化,其效果可能超过糖皮质激素。生物制剂治疗的这种优越性不能完全用糖皮质激素剂量不足或疗程有限来解释,需要进一步探讨。针对这一研究领域,我们提出了一种新的分类方法,将生物制剂对气道重塑的潜在影响分为三种时间效应:早期效应(数天至数周,主要调节炎症过程)、晚期效应(数月至数年,主要影响结构变化)和潜在预防效应(生物制剂早期治疗的结果)。为了确定生物制剂的潜在预防作用,我们呼吁开展研究,探讨早期生物制剂治疗对中重度哮喘患者气道重塑的影响,同时对临床参数、生物标志物、治疗负担和社会经济影响进行长期评估。
{"title":"Biologics and airway remodeling in asthma: early, late, and potential preventive effects","authors":"G. Varricchi, R. Poto, M. Lommatzsch, G. Brusselle, F. Braido, J. C. Virchow, G. W. Canonica","doi":"10.1111/all.16382","DOIUrl":"https://doi.org/10.1111/all.16382","url":null,"abstract":"Although airway remodeling in severe and/or fatal asthma is stil considered irreversible, its individual components as a cause of clinical symptoms and/or lung function changes remain largely unknown. While inhaled glucocorticoids have not consistently been shown to affect airway remodeling, biologics targeting specific pathways of airway inflammation have been shown to improve lung function, mucus plugging, and airway structural changes that can exceed those seen with glucocorticoids. This superiority of biologic treatment, which cannot be solely explained by insufficient doses or limited durations of glucocorticoid therapies, needs to be further explored. For this field of research, we propose a novel classification of the potential effects of biologics on airway remodeling into three temporal effects: <jats:italic>early effects</jats:italic> (days to weeks, primarily modulating inflammatory processes), <jats:italic>late effects</jats:italic> (months to years, predominantly affecting structural changes), and potential <jats:italic>preventive effects</jats:italic> (outcomes of early treatment with biologics). For the identification of potential <jats:italic>preventive effects</jats:italic> of biologics, we call for studies exploring the impact of early biological treatment on airway remodeling in patients with moderate‐to‐severe asthma, which should be accompanied by a long‐term evaluation of clinical parameters, biomarkers, treatment burden, and socioeconomic implications.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"9 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2024-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142597069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Short‐course subcutaneous treatment with birch pollen allergoids greatly improves symptom and medication scores in birch allergy 短期皮下注射桦树花粉过敏原可大大改善桦树过敏症患者的症状和用药评分
IF 12.4 1区 医学 Q1 ALLERGY Pub Date : 2024-11-09 DOI: 10.1111/all.16387
Ralph Mösges, Esther Raskopf, Ludger Klimek, Oliver Pfaar, Stefan Zielen, Elena Xenofontos, Lea Decker, Christian Neuhof, Anna Rybachuk, Cengizhan Acikel, Hacer Sahin, Silke Allekotte, Sandra del Pozo Collado, José Luis Subiza, Miguel Casanovas, Mandy Cuevas
BackgroundSubcutaneous immunotherapy has emerged as an effective option for treating allergic diseases. Here, we assessed the clinical impact of the mannan‐conjugated birch pollen polymerized allergoid T502 in birch pollen‐induced allergic rhinoconjunctivitis.MethodsIn this prospective, randomized, double‐blind placebo‐controlled phase III trial, 298 birch pollen–allergic adult patients were treated across 28 trial sites in Germany. Patients received either placebo or 23,000 mTU T502 subcutaneously over five pre‐seasonal visits. Efficacy was assessed by comparing the combined symptom and medication score (CSMS) between placebo and T502 during the peak birch pollen season 2022. Safety, tolerability and immunologic effects were also analyzed.ResultsDuring the peak birch pollen season, the median CSMS of the T502 group was reduced by 33% (p = 0.002) compared to placebo. The median daily symptom score and daily medication score were reduced by 30.4% (p < 0.001) and 56.3% (p = 0.045), respectively. Health related quality of life improved as reflected by reduction of RQLQ values by 31.5% (p < 0.0001). Production of Bet v 1 sIgG4 and Bet v 1 sIgG increased up to 6.2‐fold and 3‐fold respectively in the T502 group (p < 0.0001). The sIgE/sIgG4 ratio was strongly reduced in the T502 group at V7 (−62.9%, p < 0.0001).No fatalities nor serious adverse events were reported. In total, 16 systemic allergic reactions occurred (Grade I/II).ConclusionsTreatment with T502 significantly reduced symptoms and medication need in rhinoconjunctivitis patients. The treatment is well tolerated and safe.
背景皮下免疫疗法已成为治疗过敏性疾病的一种有效方法。在此,我们评估了甘露聚糖桦树花粉聚合类过敏原 T502 对桦树花粉诱发的过敏性鼻结膜炎的临床影响。方法在这项前瞻性、随机、双盲安慰剂对照 III 期试验中,德国 28 个试验点的 298 名桦树花粉过敏成年患者接受了治疗。患者在节前分五次皮下注射安慰剂或 23,000 mTU T502。疗效通过比较安慰剂和T502在2022年桦树花粉高峰期的综合症状和用药评分(CSMS)进行评估。结果在桦树花粉高峰期,与安慰剂相比,T502组的CSMS中位数降低了33%(p = 0.002)。每日症状评分和每日用药评分的中位数分别降低了 30.4% (p < 0.001) 和 56.3% (p = 0.045)。RQLQ值降低了31.5%(p = 0.0001),反映出与健康相关的生活质量有所改善。T502 组的 Bet v 1 sIgG4 和 Bet v 1 sIgG 产量分别增加了 6.2 倍和 3 倍(p < 0.0001)。在 V7 期,T502 组的 sIgE/sIgG4 比率大幅下降(-62.9%,p < 0.0001)。结论使用 T502 治疗可显著减轻鼻结膜炎患者的症状并减少用药需求。治疗的耐受性和安全性良好。
{"title":"Short‐course subcutaneous treatment with birch pollen allergoids greatly improves symptom and medication scores in birch allergy","authors":"Ralph Mösges, Esther Raskopf, Ludger Klimek, Oliver Pfaar, Stefan Zielen, Elena Xenofontos, Lea Decker, Christian Neuhof, Anna Rybachuk, Cengizhan Acikel, Hacer Sahin, Silke Allekotte, Sandra del Pozo Collado, José Luis Subiza, Miguel Casanovas, Mandy Cuevas","doi":"10.1111/all.16387","DOIUrl":"https://doi.org/10.1111/all.16387","url":null,"abstract":"BackgroundSubcutaneous immunotherapy has emerged as an effective option for treating allergic diseases. Here, we assessed the clinical impact of the mannan‐conjugated birch pollen polymerized allergoid T502 in birch pollen‐induced allergic rhinoconjunctivitis.MethodsIn this prospective, randomized, double‐blind placebo‐controlled phase III trial, 298 birch pollen–allergic adult patients were treated across 28 trial sites in Germany. Patients received either placebo or 23,000 mTU T502 subcutaneously over five pre‐seasonal visits. Efficacy was assessed by comparing the combined symptom and medication score (CSMS) between placebo and T502 during the peak birch pollen season 2022. Safety, tolerability and immunologic effects were also analyzed.ResultsDuring the peak birch pollen season, the median CSMS of the T502 group was reduced by 33% (<jats:italic>p</jats:italic> = 0.002) compared to placebo. The median daily symptom score and daily medication score were reduced by 30.4% (<jats:italic>p</jats:italic> &lt; 0.001) and 56.3% (<jats:italic>p</jats:italic> = 0.045), respectively. Health related quality of life improved as reflected by reduction of RQLQ values by 31.5% (<jats:italic>p</jats:italic> &lt; 0.0001). Production of <jats:italic>Bet v 1</jats:italic> sIgG4 and <jats:italic>Bet v 1</jats:italic> sIgG increased up to 6.2‐fold and 3‐fold respectively in the T502 group (<jats:italic>p</jats:italic> &lt; 0.0001). The sIgE/sIgG4 ratio was strongly reduced in the T502 group at V7 (−62.9%, <jats:italic>p</jats:italic> &lt; 0.0001).No fatalities nor serious adverse events were reported. In total, 16 systemic allergic reactions occurred (Grade I/II).ConclusionsTreatment with T502 significantly reduced symptoms and medication need in rhinoconjunctivitis patients. The treatment is well tolerated and safe.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"156 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2024-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142597068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Enhanced benefit from house dust mite immunotherapy in subjects with low serum levels of LILRA5 or CCL25 提高血清中 LILRA5 或 CCL25 含量低的受试者从屋尘螨免疫疗法中获得的益处
IF 12.4 1区 医学 Q1 ALLERGY Pub Date : 2024-11-09 DOI: 10.1111/all.16386
Véronique Bordas‐Le Floch, Anja Heider, Duygu Yazici, Sonia Luce, Cezmi Akdis, Laurent Mascarell
{"title":"Enhanced benefit from house dust mite immunotherapy in subjects with low serum levels of LILRA5 or CCL25","authors":"Véronique Bordas‐Le Floch, Anja Heider, Duygu Yazici, Sonia Luce, Cezmi Akdis, Laurent Mascarell","doi":"10.1111/all.16386","DOIUrl":"https://doi.org/10.1111/all.16386","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"127 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2024-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142597071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epigenetic training of human bronchial epithelium cells by repeated rhinovirus infections. 鼻病毒反复感染对人类支气管上皮细胞的表观遗传训练
IF 12.6 1区 医学 Q1 ALLERGY Pub Date : 2024-11-08 DOI: 10.1111/all.16388
Marua Abu Risha, Karosham D Reddy, Sai Sneha Priya Nemani, Constanze Jakwerth, Carsten Schmidt-Weber, Thomas Bahmer, Gesine Hansen, Erika von Mutius, Klaus F Rabe, Anna-Maria Dittrich, Ruth Grychtol, Nicole Maison, Bianca Schaub, Matthias V Kopp, Folke Brinkmann, Silke Meiners, Uta Jappe, Markus Weckmann

Background: Humans are subjected to various environmental stressors (bacteria, viruses, pollution) throughout life. As such, an inherent relationship exists between the effect of these exposures with age. The impact of these environmental stressors can manifest through DNA methylation (DNAm). However, whether these epigenetic effects selectively target genes, pathways, and biological regulatory mechanisms remains unclear. Due to the frequency of human rhinovirus (HRV) infections throughout life (particularly in early development), we propose the use of HRV under controlled conditions can model the effect of multiple exposures to environmental stressors.

Methods: We generated a prediction model by combining transcriptome and DNAm datasets from human epithelial cells after repeated HRV infections. We applied a novel experimental statistical design and method to systematically explore the multifaceted experimental space (number of infections, multiplicity of infections and duration). Our model included 35 samples, each characterized by the three parameters defining their infection status.

Results: Trainable genes were defined by a consistent linear directionality in DNAm and gene expression changes with successive infections. We identified 77 trainable genes which could be further explored in future studies. The identified methylation sites were tracked within a pediatric cohort to determine the relative changes in candidate-trained sites with disease status and age.

Conclusions: Repeated viral infections induce an immune training response in bronchial epithelial cells. Training-sensitive DNAm sites indicate alternate divergent associations in asthma compared to healthy individuals. Our novel model presents a robust tool for identifying trainable genes, providing a foundation for future studies.

背景:人的一生都会受到各种环境压力(细菌、病毒、污染)的影响。因此,这些暴露的影响与年龄之间存在着内在联系。这些环境应激源的影响可通过 DNA 甲基化(DNAm)表现出来。然而,这些表观遗传效应是否会选择性地针对基因、途径和生物调控机制,目前仍不清楚。由于人类鼻病毒(HRV)感染贯穿人的一生(尤其是在发育早期),我们建议在受控条件下使用HRV来模拟多次暴露于环境应激源的影响:方法:我们结合反复感染 HRV 后人类上皮细胞的转录组和 DNAm 数据集,建立了一个预测模型。我们采用了新颖的实验统计设计和方法,系统地探索了多方面的实验空间(感染次数、感染多重性和持续时间)。我们的模型包括 35 个样本,每个样本都以定义其感染状态的三个参数为特征:可训练基因的定义是,DNAm 和基因表达随连续感染发生一致的线性方向性变化。我们确定了 77 个可训练基因,可在今后的研究中进一步探讨。我们在儿科队列中追踪了已确定的甲基化位点,以确定候选训练位点随疾病状态和年龄的相对变化:结论:反复病毒感染会诱导支气管上皮细胞产生免疫训练反应。与健康人相比,训练敏感 DNAm 位点在哮喘中显示出不同的交替关联。我们的新模型为识别可训练基因提供了一个强大的工具,为未来的研究奠定了基础。
{"title":"Epigenetic training of human bronchial epithelium cells by repeated rhinovirus infections.","authors":"Marua Abu Risha, Karosham D Reddy, Sai Sneha Priya Nemani, Constanze Jakwerth, Carsten Schmidt-Weber, Thomas Bahmer, Gesine Hansen, Erika von Mutius, Klaus F Rabe, Anna-Maria Dittrich, Ruth Grychtol, Nicole Maison, Bianca Schaub, Matthias V Kopp, Folke Brinkmann, Silke Meiners, Uta Jappe, Markus Weckmann","doi":"10.1111/all.16388","DOIUrl":"https://doi.org/10.1111/all.16388","url":null,"abstract":"<p><strong>Background: </strong>Humans are subjected to various environmental stressors (bacteria, viruses, pollution) throughout life. As such, an inherent relationship exists between the effect of these exposures with age. The impact of these environmental stressors can manifest through DNA methylation (DNAm). However, whether these epigenetic effects selectively target genes, pathways, and biological regulatory mechanisms remains unclear. Due to the frequency of human rhinovirus (HRV) infections throughout life (particularly in early development), we propose the use of HRV under controlled conditions can model the effect of multiple exposures to environmental stressors.</p><p><strong>Methods: </strong>We generated a prediction model by combining transcriptome and DNAm datasets from human epithelial cells after repeated HRV infections. We applied a novel experimental statistical design and method to systematically explore the multifaceted experimental space (number of infections, multiplicity of infections and duration). Our model included 35 samples, each characterized by the three parameters defining their infection status.</p><p><strong>Results: </strong>Trainable genes were defined by a consistent linear directionality in DNAm and gene expression changes with successive infections. We identified 77 trainable genes which could be further explored in future studies. The identified methylation sites were tracked within a pediatric cohort to determine the relative changes in candidate-trained sites with disease status and age.</p><p><strong>Conclusions: </strong>Repeated viral infections induce an immune training response in bronchial epithelial cells. Training-sensitive DNAm sites indicate alternate divergent associations in asthma compared to healthy individuals. Our novel model presents a robust tool for identifying trainable genes, providing a foundation for future studies.</p>","PeriodicalId":122,"journal":{"name":"Allergy","volume":" ","pages":""},"PeriodicalIF":12.6,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142602498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gut permeability and its correlation with patient's traits and blood inflammatory markers in severe asthma: Real-world assessment from the Korean severe asthma registry-2 (KoSAR-2). 严重哮喘患者的肠道渗透性及其与患者特征和血液炎症指标的相关性:来自韩国严重哮喘登记-2(KoSAR-2)的真实世界评估。
IF 12.6 1区 医学 Q1 ALLERGY Pub Date : 2024-11-08 DOI: 10.1111/all.16392
Doo Young Choi, A-Sol Kim, So-Young Park, Joo-Hee Kim, Jin An, Jae-Woo Kwon, Sujeong Kim, Byung Keun Kim, Young-Hee Nam, Min-Suk Yang, Hye-Kyung Park, Hwa Young Lee, Hae-Sim Park, Seung-Eun Lee, Taehoon Lee, Min-Hye Kim, Chan Sun Park, Da Woon Sim, Woo-Jung Song, Sang-Heon Kim, Han-Ki Park
{"title":"Gut permeability and its correlation with patient's traits and blood inflammatory markers in severe asthma: Real-world assessment from the Korean severe asthma registry-2 (KoSAR-2).","authors":"Doo Young Choi, A-Sol Kim, So-Young Park, Joo-Hee Kim, Jin An, Jae-Woo Kwon, Sujeong Kim, Byung Keun Kim, Young-Hee Nam, Min-Suk Yang, Hye-Kyung Park, Hwa Young Lee, Hae-Sim Park, Seung-Eun Lee, Taehoon Lee, Min-Hye Kim, Chan Sun Park, Da Woon Sim, Woo-Jung Song, Sang-Heon Kim, Han-Ki Park","doi":"10.1111/all.16392","DOIUrl":"https://doi.org/10.1111/all.16392","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":" ","pages":""},"PeriodicalIF":12.6,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142602499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
DNA hypomethylation of Th17 cells by ambient particulate pollutants enhances neutrophil recruitment in murine models of allergic airway inflammation 在过敏性气道炎症的小鼠模型中,环境颗粒污染物对 Th17 细胞的 DNA 低甲基化作用会增强中性粒细胞的招募
IF 12.4 1区 医学 Q1 ALLERGY Pub Date : 2024-11-07 DOI: 10.1111/all.16389
Bin Li, Yuan Zhang, Nannan Huang, Jing Wang, Xianan Zhang, Qingtao Meng, Jiajia Wang, Chengshuo Wang, Xiaobo Li, Rui Chen, Luo Zhang
{"title":"DNA hypomethylation of Th17 cells by ambient particulate pollutants enhances neutrophil recruitment in murine models of allergic airway inflammation","authors":"Bin Li, Yuan Zhang, Nannan Huang, Jing Wang, Xianan Zhang, Qingtao Meng, Jiajia Wang, Chengshuo Wang, Xiaobo Li, Rui Chen, Luo Zhang","doi":"10.1111/all.16389","DOIUrl":"https://doi.org/10.1111/all.16389","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"28 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142597116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Basophil activation test: How many basophils are enough? 嗜碱性粒细胞活化测试:嗜碱性粒细胞的数量够吗?
IF 12.6 1区 医学 Q1 ALLERGY Pub Date : 2024-11-06 DOI: 10.1111/all.16391
Léonard Bezinge, Dominik Vogt, Anna Melone, Maximilien Lartigue, Cédric Giegelmann, Thomas Schuster, Michael Schneider, Michele Romano, Christian-Benedikt Gerhold, Michael A Gerspach, Christina Bauer
{"title":"Basophil activation test: How many basophils are enough?","authors":"Léonard Bezinge, Dominik Vogt, Anna Melone, Maximilien Lartigue, Cédric Giegelmann, Thomas Schuster, Michael Schneider, Michele Romano, Christian-Benedikt Gerhold, Michael A Gerspach, Christina Bauer","doi":"10.1111/all.16391","DOIUrl":"https://doi.org/10.1111/all.16391","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":" ","pages":""},"PeriodicalIF":12.6,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142581122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Investigation of the diagnostic accuracy of basophil activation test for allergic phenotypes of rhinitis. 嗜碱性粒细胞活化测试对鼻炎过敏表型诊断准确性的研究。
IF 12.6 1区 医学 Q1 ALLERGY Pub Date : 2024-11-05 DOI: 10.1111/all.16390
Almudena Testera-Montes, Adriana Ariza, Rosa Alba Sola-Martinez, Carlos Jose Aranda, Guillermo Bentabol-Ramos, Dulce Sanchez-Torralvo, Cristobalina Mayorga, Maria Jose Torres, Ibon Eguiluz-Gracia, Carmen Rondon

Introduction: Basophil activation test (BAT) might be an alternative to nasal allergen challenge (NAC) to identify the allergic etiology in rhinitis patients. Here, we investigate the diagnostic performance of BAT for allergic phenotypes of rhinitis.

Methods: Rhinitis patients and healthy controls were subjected to NAC with Dermatophagoides pteronyssinus (DP), Alternaria alternata (AA), grass (GP) and olive (OP) pollens. Rhinitis subjects also underwent skin prick test (SPT) with relevant allergens. Patients were classified into allergic rhinitis (AR, positive NAC and SPT), local allergic rhinitis (LAR, positive NAC and negative SPT), dual allergic rhinitis (DAR, defined as AR for ≥1 allergen and LAR for ≥1 allergen), and non-allergic rhinitis (NAR, negative NAC and SPT) phenotypes. BAT with DP, AA, GP and OP was conducted in study individuals and compared with NAC results.

Results: A total of 47 AR, 31 DAR, 26 LAR, 12 NAR and 21 control subjects were recruited. The best positivity cut-offs of BAT for DP-, AA-, GP- and OP-driven allergy (all phenotypes) were a %CD63 cells of 8.650, 14.250, 26.200, and 12.780, respectively (AUC 0.851, 0.701, 0.887, and 0.921, respectively). Sensitivity, specificity, negative and positive predictive values of BAT (all phenotypes) ranged 43.5%(AA)-83.3%(OP), 88.9%(GP)-100%(AA), 87%(GP)-100%(AA), and 61.1%(DP)-80.0%(pollens), respectively. BAT identified 79%-100% of SPT-positive allergies (AR and DAR), and 25%-75% of SPT-negative allergies (LAR and DAR), while ≤10% of NAR/HC subjects tested positive. BAT positivity correlated with rhinitis severity in LAR patients (p = 0.018), and associated with conjunctivitis (p = 0.015) in allergic subjects.

Conclusion: BAT can replace NAC for AR confirmation, and limit the number of NAC required for LAR and DAR diagnosis. BAT can demonstrate sIgE in SPT-negative allergies.

导言:嗜碱性粒细胞活化试验(BAT)可替代鼻过敏原挑战试验(NAC)来确定鼻炎患者的过敏病因。在此,我们研究了 BAT 对鼻炎过敏表型的诊断性能:方法:对鼻炎患者和健康对照组进行鼻腔过敏原检测,检测对象包括Dermatophagoides pteronyssinus (DP)、Alternaria alternata (AA)、草花粉 (GP) 和橄榄花粉 (OP)。鼻炎受试者还接受了相关过敏原的皮肤点刺试验(SPT)。患者被分为过敏性鼻炎(AR,NAC 和 SPT 阳性)、局部过敏性鼻炎(LAR,NAC 阳性,SPT 阴性)、双重过敏性鼻炎(DAR,定义为≥1 种过敏原的 AR 和≥1 种过敏原的 LAR)和非过敏性鼻炎(NAR,NAC 和 SPT 阴性)表型。对研究个体进行了含有 DP、AA、GP 和 OP 的 BAT 检测,并与 NAC 结果进行了比较:结果:共招募了 47 名 AR 受试者、31 名 DAR 受试者、26 名 LAR 受试者、12 名 NAR 受试者和 21 名对照组受试者。BAT对DP、AA、GP和OP过敏(所有表型)的最佳阳性临界值分别为%CD63细胞8.650、14.250、26.200和12.780(AUC分别为0.851、0.701、0.887和0.921)。BAT 的灵敏度、特异性、阴性和阳性预测值(所有表型)分别为 43.5%(AA)-83.3%(OP)、88.9%(GP)-100%(AA)、87%(GP)-100%(AA)和 61.1%(DP)-80.0%(花粉)。BAT 鉴定出 79%-100% 的 SPT 阳性过敏(AR 和 DAR)和 25%-75% 的 SPT 阴性过敏(LAR 和 DAR),而 NAR/HC 受试者中检测呈阳性的比例≤10%。BAT 阳性与 LAR 患者的鼻炎严重程度相关(p = 0.018),与过敏性受试者的结膜炎相关(p = 0.015):结论:BAT 可替代 NAC 用于 AR 确认,并限制 LAR 和 DAR 诊断所需的 NAC 数量。BAT 可在 SPT 阴性的过敏症中显示 sIgE。
{"title":"Investigation of the diagnostic accuracy of basophil activation test for allergic phenotypes of rhinitis.","authors":"Almudena Testera-Montes, Adriana Ariza, Rosa Alba Sola-Martinez, Carlos Jose Aranda, Guillermo Bentabol-Ramos, Dulce Sanchez-Torralvo, Cristobalina Mayorga, Maria Jose Torres, Ibon Eguiluz-Gracia, Carmen Rondon","doi":"10.1111/all.16390","DOIUrl":"https://doi.org/10.1111/all.16390","url":null,"abstract":"<p><strong>Introduction: </strong>Basophil activation test (BAT) might be an alternative to nasal allergen challenge (NAC) to identify the allergic etiology in rhinitis patients. Here, we investigate the diagnostic performance of BAT for allergic phenotypes of rhinitis.</p><p><strong>Methods: </strong>Rhinitis patients and healthy controls were subjected to NAC with Dermatophagoides pteronyssinus (DP), Alternaria alternata (AA), grass (GP) and olive (OP) pollens. Rhinitis subjects also underwent skin prick test (SPT) with relevant allergens. Patients were classified into allergic rhinitis (AR, positive NAC and SPT), local allergic rhinitis (LAR, positive NAC and negative SPT), dual allergic rhinitis (DAR, defined as AR for ≥1 allergen and LAR for ≥1 allergen), and non-allergic rhinitis (NAR, negative NAC and SPT) phenotypes. BAT with DP, AA, GP and OP was conducted in study individuals and compared with NAC results.</p><p><strong>Results: </strong>A total of 47 AR, 31 DAR, 26 LAR, 12 NAR and 21 control subjects were recruited. The best positivity cut-offs of BAT for DP-, AA-, GP- and OP-driven allergy (all phenotypes) were a %CD63 cells of 8.650, 14.250, 26.200, and 12.780, respectively (AUC 0.851, 0.701, 0.887, and 0.921, respectively). Sensitivity, specificity, negative and positive predictive values of BAT (all phenotypes) ranged 43.5%(AA)-83.3%(OP), 88.9%(GP)-100%(AA), 87%(GP)-100%(AA), and 61.1%(DP)-80.0%(pollens), respectively. BAT identified 79%-100% of SPT-positive allergies (AR and DAR), and 25%-75% of SPT-negative allergies (LAR and DAR), while ≤10% of NAR/HC subjects tested positive. BAT positivity correlated with rhinitis severity in LAR patients (p = 0.018), and associated with conjunctivitis (p = 0.015) in allergic subjects.</p><p><strong>Conclusion: </strong>BAT can replace NAC for AR confirmation, and limit the number of NAC required for LAR and DAR diagnosis. BAT can demonstrate sIgE in SPT-negative allergies.</p>","PeriodicalId":122,"journal":{"name":"Allergy","volume":" ","pages":""},"PeriodicalIF":12.6,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142581123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Allergy
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1